<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 467 from Anon (session_user_id: 15b530ebcda71e2e3f7639cda92c2d039f1ba64b)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 467 from Anon (session_user_id: 15b530ebcda71e2e3f7639cda92c2d039f1ba64b)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p>DNA methylation is epigenetic process that occurs by adding methyl group on 5’ of cytosine within CpG dinucleotides. CpGs clustered into CpG islands and are often at promoters of genes. CpG islands are usually kept free of methylation. Hemimethylated DNA is supstrate for methyltransferase. MeCpGs can prohibit transcription factor binding and alter gene expression. DNA methylation of promoter regions inversibly correlated with gene expression. Methylation silences gene expression. </p><p>Cancer is caused geneticaly and epigeneticaly by activation of oncogenes (overexpression of genes) or inactivation of tumor suppressor genes. The epigenome of cancer cells display numerous alterations in comparison to the epigenome of their normal counterpart. Changes in DNA methylation include a genome-wide loss and a regional gain of DNA methylation. This causes genomic instability and deregulation of tissue specific and imprinted genes and silencing tumor supressor gene: controlling cell cycle, apoptosis or DNA repair by hypermethylation of their promoter CpG islands. </p><p>In normal cell CpG islands are usually hypomethylated while in cancer cells the CpG island are more likely to be hypermethylated which leads to silencing of the underlying gene. DNA methylation is mitotically heritable and there is increases in CpG island methylation as cancer progress. CpG islands shores are also hypermethylated in cancer. DNA methylation is mutagenic, as methylated cytosine is easily deaminated to tymidine. DNA methylation silence tumour suppressor genes. In cancer cell there is also CpG poor promotor hypomethylation associated with activation of the associated genes. </p><p>In normal cells repetititive elements and intergenic regions are usually methylated maintaining genomic integrity and stability while in cancer cells these elements are hypomethylated which cause genomic instability that leads to rearrangement of the chromosomes (deletions, insertions and translocations) and activation of these regions causing jumping around genomes and incorporating on other places within genome. <span> </span></p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p><span>Decitabine belongs to the class of DNMT inhibitors. Decotabine is a hypomethylating or demethylating agent. It demethylates DNA by inhibiting DNA methyltransferase. Decitabin is cytidine analog that is incorporated into DNA during replication and irreversibly binds DNMT that cannot be released. So the methyltransferase is inhibited. Cancer cells that divide rapidly are more likely to be affected and in that way it has anti-tumour effect.  </span></p></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p>Dr Baylin’s speculated that epigenetic drugs altered tumour cells making them more susceptible to standard chemotherapy. Epigenetic changes are passed on during cell divisions to daughter and granddaughter cells until they are actively erased and do not return. Therefore epigenetic therapies can effect changes which stop cancer growth without having to kill all its cells. </p><p>Sensitive period is a period when the environmental influences have the biggest impact and when epigenetic reprogramming occurs. The most sensitive period is early embryonic development and period of germ cell development. If during that period there is an influence from the environment it can bring serious damage. Mitotic heritability is required for the bigger influence on the organism otherwise only cells that are exposed are going to be affected and influenced and will be lost by following cell divisions. <span>Sensitive period is a period of intensive growth and development and cell division and drugs will affect whole organism. Especially it is not advisable to take drugs during germ cell development and pregnancy as the consequences should be taken in serious considerations. The embrio could be seriously damage as well as next generations if there is influence on germ cells. </span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p><span>On paternal allele CTCF is not binding as ICR is methylated so enhancer binds to Igf2 and Igf2 is expressed. In normal cells ICR is methylated on paternal allele and unmethylated on maternal allele. Therefore CTCF binds these elements and enhancer acts on H19 and Igf2 is silenced on maternal allele. In Wilm’s tumour imprinting is disrupted by hypermethylation of ICR on maternal allele therefore Igf2 is expressed from maternal allele too, which leads to double dose of Igf2 expression and Igf2 is growth promoting. Cancer cells exhibit loss of imprinting and genes are express or suppress from parental alleles that can result in loss of expression of growth restriction genes or overexpression of growth promoting genes by alterations in methylation of ICR. </span></p></div>
  </body>
</html>